AnaptysBio (ANAB) News Today $18.62 -0.25 (-1.34%) Closing price 03:59 PM EasternExtended Trading$19.20 +0.58 (+3.13%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% - Here's WhyAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% - Here's WhyFebruary 19 at 10:35 PM | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in JanuaryFebruary 19 at 1:53 AM | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Short Interest UpdateAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a decrease of 8.6% from the January 15th total of 6,600,000 shares. Approximately 23.3% of the shares of the company are short sold. Based on an average daily trading volume, of 662,000 shares, the days-to-cover ratio is currently 9.1 days.February 17, 2025 | marketbeat.comQ1 Earnings Forecast for AnaptysBio Issued By HC WainwrightFebruary 17, 2025 | americanbankingnews.comQ1 Earnings Estimate for AnaptysBio Issued By HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for AnaptysBio in a report released on Wednesday, February 12th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($1.56) per share for tFebruary 17, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Receives Outperform Rating from WedbushFebruary 15, 2025 | americanbankingnews.comWells Fargo & Company Raises AnaptysBio (NASDAQ:ANAB) Price Target to $51.00February 15, 2025 | americanbankingnews.comWells Fargo & Company Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock PriceWells Fargo & Company boosted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday.February 14, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5% - Still a Buy?AnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5% - Should You Buy?February 13, 2025 | marketbeat.comAnaptysBio price target raised to $51 from $40 at Wells FargoFebruary 13, 2025 | markets.businessinsider.comH.C. Wainwright lifts AnaptysBio stock target to $22, keeps NeutralFebruary 13, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating from WedbushWedbush reaffirmed an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Wednesday.February 13, 2025 | marketbeat.comRosnilimab shows promise in rheumatoid arthritis trialFebruary 13, 2025 | msn.comAnaptysBio stock soars on positive RA trial resultsFebruary 13, 2025 | investing.comTruist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA dataFebruary 13, 2025 | markets.businessinsider.comAnaptysBio price target raised to $22 from $19 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comAnaptys surges as arthritis therapy succeeds in mid-stage trialFebruary 13, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Given Outperform Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday.February 12, 2025 | marketbeat.comAnaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 MonthsFebruary 12, 2025 | globenewswire.comAnaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025February 11, 2025 | globenewswire.comWedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)February 7, 2025 | markets.businessinsider.comShareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years agoFebruary 5, 2025 | finance.yahoo.comWedbush Analysts Boost Earnings Estimates for AnaptysBioAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Stock analysts at Wedbush upped their Q1 2025 EPS estimates for shares of AnaptysBio in a research note issued to investors on Monday, February 3rd. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per sFebruary 5, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Upgraded to "Strong-Buy" at Wolfe ResearchWolfe Research raised shares of AnaptysBio to a "strong-buy" rating in a report on Monday.February 5, 2025 | marketbeat.comH.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 targetFebruary 5, 2025 | msn.comAnalyst Expectations For AnaptysBio's FutureFebruary 5, 2025 | benzinga.comWolfe Research Initiates Coverage of AnaptysBio (ANAB) with Outperform RecommendationFebruary 5, 2025 | msn.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Should You Buy?AnaptysBio (NASDAQ:ANAB) Shares Gap Up - Time to Buy?February 4, 2025 | marketbeat.comWolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB)Wolfe Research started coverage on shares of AnaptysBio in a report on Tuesday. They issued an "outperform" rating and a $25.00 target price for the company.February 4, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $19.00 price target on shares of AnaptysBio in a research report on Tuesday.February 4, 2025 | marketbeat.comFY2029 Earnings Estimate for AnaptysBio Issued By WedbushAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings per share estimates for shares of AnaptysBio in a research report issued on Monday, February 3rd. Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($4.04) perFebruary 4, 2025 | marketbeat.comVanda, Anaptys Join on Development PactFebruary 3, 2025 | baystreet.caAnaptysBio initiated with an Outperform at Wolfe ResearchFebruary 3, 2025 | markets.businessinsider.comAnaptys to Present at the Guggenheim SMID Cap Biotech ConferenceFebruary 3, 2025 | globenewswire.comVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistFebruary 3, 2025 | prnewswire.comVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistFebruary 3, 2025 | globenewswire.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by AnalystsAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and eight have issued a buyJanuary 31, 2025 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Down 4.5% - Time to Sell?AnaptysBio (NASDAQ:ANAB) Trading Down 4.5% - Time to Sell?January 29, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)JPMorgan Chase & Co. raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 191.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,744 shares of the biotechnology company's stock after purchasingJanuary 25, 2025 | marketbeat.comAssenagon Asset Management S.A. Cuts Position in AnaptysBio, Inc. (NASDAQ:ANAB)Assenagon Asset Management S.A. lessened its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 30.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 331,758 shares of the biotechnology company's sJanuary 21, 2025 | marketbeat.comLeerink Partners Remains a Buy on AnaptysBio (ANAB)January 20, 2025 | markets.businessinsider.comAnaptys to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and eight have issued aJanuary 6, 2025 | marketbeat.comEcor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockJanuary 3, 2025 | insidertrades.comEcor1 Capital, Llc Purchases 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.January 2, 2025 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc Purchases 65,184 SharesAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc purchased 65,184 shares of the stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares of the company's stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 2, 2025 | marketbeat.comState Street Corp Sells 60,670 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)State Street Corp decreased its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 906,182 shares of the biotechnology compDecember 22, 2024 | marketbeat.comFranklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Franklin Resources Inc. decreased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 23.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 354,370 shares of the bioDecember 21, 2024 | marketbeat.comAnaptysBio price target lowered to $36 from $66 at JPMorganDecember 20, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. reduced their price target on AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a report on Thursday.December 19, 2024 | marketbeat.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.250.60▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼114▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ImmunityBio News Today Arrowhead Pharmaceuticals News Today HUTCHMED News Today Edgewise Therapeutics News Today Mirum Pharmaceuticals News Today Amneal Pharmaceuticals News Today Kymera Therapeutics News Today Gemini Therapeutics News Today Protagonist Therapeutics News Today Mesoblast News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
